DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on May 12, 2008; DOI: 10.1124/dmd.108.021873

0090-9556/08/3608-1587-1593$20.00
DMD 36:1587-1593, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.021873v1
36/8/1587    most recent
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Stevens, J. C.
Right arrow Articles by Hines, R. N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stevens, J. C.
Right arrow Articles by Hines, R. N.

Developmental Changes in Human Liver CYP2D6 Expression

Jeffrey C. Stevens, Sandra A. Marsh, Matthew J. Zaya, Karen J. Regina, Karthika Divakaran, Min Le, and Ronald N. Hines

Pfizer Corporation, Global Research and Development, Chesterfield, Missouri (J.C.S., S.A.M., M.J.Z., and K.J.R.); and Departments of Pediatrics and Pharmacology/Toxicology and Children's Research Institute, Medical College of Wisconsin and Children's Hospital and Health System, Milwaukee, Wisconsin (K.D., M.L., R.N.H.)

Within the human cytochrome P450 family, specific forms show developmental expression patterns that can affect drug clearance, efficacy, and safety. The objective of this study was to use dextromethorphan O-demethylase activity and quantitative Western blotting to identify CYP2D6 developmental expression patterns in a large (n = 222) and developmentally diverse set of pediatric liver samples. Immunodetectable levels of CYP2D6 protein determined for selected samples across all age categories showed a significant correlation with the corresponding dextromethorphan O-demethylase activity. Of gender, ethnicity, postmortem interval, and genotype, only increasing gestational age was associated with CYP2D6 activity and protein content in prenatal samples. In contrast, both age and genotype were associated with CYP2D6 expression in postnatal samples. CYP2D6 expression in liver samples from neonates less than 7 days of age was higher than that observed in first and second trimester samples, but not significantly higher than third trimester fetal samples. In contrast, expression in postnatal samples greater than 7 days of age was substantially higher than that for any earlier age category. Higher CYP2D6 expression also was observed in liver samples from Caucasians versus African Americans. Finally, using phenotype categories inferred from genotype, CYP2D6 activity was higher in postnatal samples predicted to be extensive or intermediate metabolizers versus poor metabolizers. These results suggest that age and genetic determinants of CYP2D6 expression constitute significant determinants of interindividual variability in CYP2D6-dependent metabolism during ontogeny.

Address correspondence to: Dr. Ronald N. Hines, Medical College of Wisconsin, TBRC/CRI/CPPT, 8701 Watertown Plank Rd., Milwaukee, WI 53226. E-mail: rhines{at}mcw.edu




eLetters:

Read all eLetters

Developmental changes in CYP2D6 expression in early life: an in vivo approach to assess co-variates
Karel Allegaert, et al.
DMD Online, 5 Jun 2008 [Full text]

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.